Danuta Ostalska-Nowicka
Overview
Explore the profile of Danuta Ostalska-Nowicka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sobiak J, Resztak M, Sikora W, Zachwieja J, Ostalska-Nowicka D
Pharmacol Rep
. 2024 Jun;
76(4):910.
PMID: 38916851
No abstract available.
2.
Soltysiak J, Skowronska B, Mackowiak-Lewandowicz K, Blumczynski A, Elzbieta K, Ostalska-Nowicka D, et al.
Pediatr Nephrol
. 2024 Jun;
39(10):3037-3047.
PMID: 38864872
Background: This study aimed to evaluate the blood pressure (BP) status, including arterial stiffness parameters, hemodynamic indicators, circadian profile, and its association with albuminuria in adolescents with type 1 diabetes...
3.
Sobiak J, Resztak M, Sikora W, Zachwieja J, Ostalska-Nowicka D
Pharmacol Rep
. 2024 Mar;
76(3):600-611.
PMID: 38485859
Background: Saliva sampling is one of the methods of therapeutic drug monitoring for mycophenolic acid (MPA) and its metabolite, mycophenolic acid glucuronide (MPAG). The study describes the liquid chromatography tandem...
4.
Sobiak J, Resztak M, Banasiak J, Zachwieja J, Ostalska-Nowicka D
Pharmacol Rep
. 2023 Mar;
75(3):726-736.
PMID: 36905501
Background: For therapeutic drug monitoring (TDM) of mycophenolic acid (MPA), which is frequently proposed, saliva might be a suitable and easy-to-obtain biological matrix. The study aimed to validate an HPLC...
5.
Sobiak J, Zero P, Zachwieja J, Ostalska-Nowicka D, Pawinski T
Clin Exp Pharmacol Physiol
. 2023 Feb;
50(6):486-496.
PMID: 36846865
In paediatric patients, there is no data on the recommended area under the concentration-time curve from 0 to 12 h (AUC ) for free mycophenolic acid (fMPA), which is the...
6.
Soltysiak J, Krzysko-Pieczka I, Gertig-Kolasa A, Mularz E, Skowronska B, Ostalska-Nowicka D, et al.
Pediatr Nephrol
. 2022 Oct;
38(5):1643-1652.
PMID: 36227434
Background: Diabetic ketoacidosis (DKA) and hyperglycaemia without ketoacidosis are common acute complications of diabetes. Their association with acute kidney injury (AKI) and diabetic kidney disease (DKD) was studied. Methods: The...
7.
Sobiak J, Resztak M, Zachwieja J, Ostalska-Nowicka D
Clin Exp Pharmacol Physiol
. 2022 Jul;
49(11):1197-1208.
PMID: 35877984
Some studies have shown that the area under the concentration-time curve (AUC) of mycophenolic acid (MPA) should be higher for children with nephrotic syndrome (NS) than after renal transplantation. The...
8.
Mackowiak-Lewandowicz K, Ostalska-Nowicka D, Zaorska K, Kaczmarek E, Zachwieja J, Witt M, et al.
Pediatr Nephrol
. 2022 Feb;
37(10):2479-2488.
PMID: 35211791
Background: Glomerular hyperfiltration, initiating development of obesity-related glomerulopathy, results in an enlargement of the glomeruli and unsealing of the filtration barrier. It can be followed by adaptive focal segmental glomerulosclerosis...
9.
Mackowiak-Lewandowicz K, Ostalska-Nowicka D, Zachwieja J, Paszynska E
J Clin Med
. 2021 Aug;
10(16).
PMID: 34442019
(1) Background: A rarely discussed effect of obesity-related glomerulopathy (ORG) may slowly lead to irreversible glomerular damage and the development of chronic kidney disease. These patients need to undertake medical...
10.
Sobiak J, Resztak M, Chrzanowska M, Zachwieja J, Ostalska-Nowicka D
Molecules
. 2021 Jul;
26(12).
PMID: 34207320
We evaluated mycophenolic acid (MPA) limited sampling strategies (LSSs) established using multiple linear regression (MLR) in children with nephrotic syndrome treated with mycophenolate mofetil (MMF). MLR-LSS is an easy-to-determine approach...